Back to database

Tirzepatide

Also known as: Mounjaro, Zepbound

GLP-1 / Weight LossFDA ApprovedSubcutaneous

A dual incretin agonist targeting both GIP and GLP-1 receptors. Shows superior weight loss and glycemic control compared to GLP-1-only agonists.

Molecular Weight

4813.5 Da

Half-Life

~5 days

Sequence

Dual GIP/GLP-1 receptor agonist (39 amino acids)

Mechanism of Action

Dual agonism of GIP and GLP-1 receptors enhances insulin sensitivity, reduces appetite, and improves metabolic function through complementary pathways.

Dosing Protocol

Start 2.5mg/week for 4 weeks, titrate to 5mg, then 7.5mg, 10mg, 12.5mg, up to 15mg/week.

Open peptide calculator
Reconstitution

Research-grade: 5mg vial + 2mL BAC water.

Storage

Refrigerate 2-8°C. Do not freeze.

Side Effects
  • ●Nausea
  • ●Diarrhea
  • ●Decreased appetite
  • ●Injection site reactions
Key Research Findings
  • ●SURMOUNT-1: up to 22.5% weight reduction
  • ●Superior to semaglutide in head-to-head trials
  • ●Improved insulin sensitivity beyond weight loss alone

Research Use Only

This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.